Thomas Pieber News Today

Investegate announcements from Positive headline results for AT278 clinical trial

Arecor Therapeutics plc AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES AT278 demonstrates...

Today, Boehringer Ingelheim and CBmed GmbH Center for Biomarker Research in Medicine (CBmed) announced a long-term strategic partnership. Jointly the partners will apply translational medicine approaches to accelerate the development of first-in-class medicines to transform the lives of people with cancer and ...

Hypoglycemia rates didnt differ between weekly insulin icodec and daily glargine even when intentionally doubling and tripling the doses, although those parts of the study each lasted just 1 day.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Investegate announcements from Arecor Therapeutics, ARECOR TO HOST KOL WEBINAR

Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes 3 , 2021 – Zealand Pharma A/S (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that Diabetes Care has published results from its Phase 3 trial evaluating dasiglucagon for the treatment of severe hypo...

Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes 3 , 2021 – Zealand Pharma A/S (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that Diabetes Care has published results from its Phase 3 trial evaluating dasiglucagon for the treatment of severe hypo...

NEW YORK, Feb. 24, 2021 /PRNewswire/ -- JDRF International, the Lupus Research Alliance and the National Multiple Sclerosis Society joined forces to accelerate research and discovery in autoimmunity and are

Posted on 7691 Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diab...